ABSTRACT
Introduction: The COVID-19 pandemic and pre-eclampsia both present significant health challenges worldwide, with emerging evidence suggesting a genetic interlinkage that could illuminate new therapeutic avenues. This study aims to explore the genetic relationship between the severity of COVID-19 and pre-eclampsia, with a focus on Single Nucleotide Polymorphisms (SNPs) in the NTSR1 gene and mechanisms of calcium ion transport. Method: We employed a combination of genetic epidemiology and molecular biology techniques, including comprehensive bibliometric analysis and Mendelian Randomization, to assess the correlation between specific SNPs related to the NTSR1 gene and the severity of both COVID-19 and pre-eclampsia. Result: Our findings reveal a significant genetic correlation between the severity of COVID-19 and pre-eclampsia, underscored by SNPs associated with the NTSR1 gene and calcium ion transport. This correlation suggests a shared genetic foundation that could exacerbate both conditions, providing insights into potential molecular interactions involved. Conclusion: The identification of shared genetic pathways between COVID-19 and pre-eclampsia highlights the importance of genetic insights in developing targeted therapeutic interventions. These results open up new avenues for the mitigation of these conditions, emphasizing the role of genetic epidemiology in shaping future healthcare strategies.
Subject(s)
COVID-19 , EclampsiaABSTRACT
Background：Hypofractionated whole breast irradiation (HF-WBI) can achieve the same treatment effect as conventional fractionated whole breast irradiation (CF-WBI) within limits , without increasing adverse reactions. Because of its characteristics of reducing the number of radiation therapy (RT) during the COVID-19 Pandemic, it is recommended as the first choice of treatment for patients with early breast cancer after breast conserving surgery. However, the choice of RT is still under exploration. Here, we conducted a network meta-analysis to evaluate the problem comprehensively using data from new randomized trials. Methods: We analyzed data from eligible studies for published events for ipsilateral breast tumor recurrence (IBTR), distant metastasis, total deaths, and non-breast cancer-related deaths. Statistical analysis was performed using a fixed-effects or random-effects model in cases of low and high heterogeneity, respectively. Network meta-analysis was conducted using a node-splitting model for two-category data among three RTs based on a Bayesian approach.Results: 16 studies with 23,418 patients were included. For IBTR, pairwise comparison showed that CF-WBI was significantly better than PBI, and HF-WBI was similar to CF-WBI. HF-WBI was superior to PBI, but the difference was not significant. However, indirect comparison of three RTs by network meta-analysis showed that HF-WBI was significantly better than PBI (OR=0.67, CI95%: 0.46–0.95). Paired and network meta-analyses found no significant differences in other endpoints among three radiotherapies. Conclusion: This meta-analysis demonstrated PBI was associated with increased IBTR compared with HF-WBI or CF-WBI in early-stage breast cancer patients.